---
title: "Guohai Securities Sticks to Its Buy Rating for Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285489230.md"
description: "Guohai Securities has reaffirmed its Buy rating for Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637), setting a price target of HK$339.55. The stock closed at HK$258.00. The overall analyst consensus for the company is a Strong Buy, with an average price target of HK$312.04."
datetime: "2026-05-07T05:15:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285489230.md)
  - [en](https://longbridge.com/en/news/285489230.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285489230.md)
---

# Guohai Securities Sticks to Its Buy Rating for Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)

In a report released yesterday, from Guohai Securities maintained a Buy rating on Fujian Haixi Pharmaceuticals Co., Ltd. Class H, with a price target of HK$339.55. The company’s shares closed yesterday at HK$258.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fujian Haixi Pharmaceuticals Co., Ltd. Class H with a HK$312.04 average price target.

### Related Stocks

- [02637.HK](https://longbridge.com/en/quote/02637.HK.md)
- [000750.CN](https://longbridge.com/en/quote/000750.CN.md)

## Related News & Research

- [Fujian Haixi Advances First-in-Class Oral Retinal Drug HXP056 Into Phase II](https://longbridge.com/en/news/280291010.md)
- [Northeast Securities Reaffirms Their Buy Rating on Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637)](https://longbridge.com/en/news/285826256.md)
- [Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637) Receives a Buy from SWS Res](https://longbridge.com/en/news/284073168.md)
- [Fujian Haixi Pharmaceuticals Revamps Hong Kong Company Secretarial Roles](https://longbridge.com/en/news/278064864.md)
- [Bravida Advances SEK 100 Million Share Buyback to Optimize Capital Structure](https://longbridge.com/en/news/286803958.md)